Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Insulin ointment shows promise for speeding up wound healing in rare blistering disease

NCT ID NCT07461103

Symptom relief Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether applying insulin directly to skin sores helps them heal faster in people with pemphigus vulgaris, a rare autoimmune blistering disease. Twenty patients each had three similar sores treated with either long-acting insulin, short-acting insulin, or a saltwater control for 14 days. The goal was to see which treatment led to the quickest healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

Jun 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of pemphigus vulgaris by clinical and histopathological criteria * Presence of erosions and/or ulcers on skin and/or mucous membranes * At least three lesions of comparable location, size, depth, and healing stage Exclusion Criteria: * Lesions with clinical signs of secondary infection (purulence, surrounding erythema, fever) * Uncontrolled general condition significantly affecting wound healing (e.g., hypoalbuminemia) * Known allergy to insulin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune blistering disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune bullous skin disease Insulin Resistance pemphigus pemphigus vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune blistering disease Pemphigus vulgaris Skin erosion

Contacts and locations

Locations

  • Alexandria main university hospital, Department of Dermatology and Venereology

    Alexandria, 22301, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.